基础医学与临床 ›› 2018, Vol. 38 ›› Issue (7): 1016-1019.

• 短篇综述 • 上一篇    下一篇

嵌合抗原受体T细胞治疗原发性肝癌的研究进展

许洋1,张雅敏1,王建2,刘子荣1   

  1. 1. 天津市第一中心医院
    2. 天津一中心
  • 收稿日期:2017-05-12 修回日期:2017-07-19 出版日期:2018-07-05 发布日期:2018-06-29
  • 通讯作者: 张雅敏 E-mail:zhangyamin@medmail.com.cn
  • 基金资助:
    国家自然科学基金;天津市应用基础与前沿技术研究计划;国家临床重点专科建设基金资助项目(器官移植);中国肝炎防治基金会天晴肝病研究基金

Research progress of chimeric antigen receptor T cells in the treatment of primary liver cancer

  • Received:2017-05-12 Revised:2017-07-19 Online:2018-07-05 Published:2018-06-29

摘要: CAR-T技术作为免疫治疗的一种,从最早期的第1代发展至目前的第4代,其细胞毒性和抗肿瘤免疫效应大大增强,但也暴露出相应的安全问题,其在原发性肝癌治疗的相关研究中展现出一定优势,预示着在精准个体化肝癌治疗时代,免疫治疗尤其CAR-T技术联合手术治疗、放化疗和局部治疗等综合治疗将会发挥更强有力的作用。

关键词: 原发性肝癌, 免疫治疗, CAR-T疗法, 靶点抗原

Abstract: CAR-T technology as a kind of immunotherapy, from the earlist generation of the first to the current fourth generation, its cytotoxic, anti-tumor immune effect greatly enhanced, but also challenged by safety issues. It shows a certain advantage in the therapy of hepatocellular carcinoma. It indicates that the era of precise individualized liver cancer treatment, immune therapy, especially CAR-T technology combined with surgery, radiotherapy and chemotherapy, local treatment and other comprehensive treatment will play a more powerful role.

Key words: Primary liver cancer, immune therapy, CAR-T therapy, Target antigen